These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

112 related articles for article (PubMed ID: 12901560)

  • 1. Phagocytosis of synthetic particulate vaccine delivery systems to program dendritic cells.
    Thiele L; Merkle HP; Walter E
    Expert Rev Vaccines; 2002 Aug; 1(2):215-26. PubMed ID: 12901560
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Induction and direction of immune responses by vaccine adjuvants.
    Schijns VE
    Crit Rev Immunol; 2001; 21(1-3):75-85. PubMed ID: 11642615
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Nasal vaccine innovation.
    Jabbal-Gill I
    J Drug Target; 2010 Dec; 18(10):771-86. PubMed ID: 21047271
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Poly(gamma-glutamic acid) nanoparticles as an efficient antigen delivery and adjuvant system: potential for an AIDS vaccine.
    Wang X; Uto T; Akagi T; Akashi M; Baba M
    J Med Virol; 2008 Jan; 80(1):11-9. PubMed ID: 18041033
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Oral vaccination and vaccine-entrapped microparticle delivery system].
    Li FQ; Fei YB; Su H; Hu JH
    Yao Xue Xue Bao; 2007 Mar; 42(3):245-51. PubMed ID: 17520821
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immunity in response to particulate antigen-delivery systems.
    Storni T; Kündig TM; Senti G; Johansen P
    Adv Drug Deliv Rev; 2005 Jan; 57(3):333-55. PubMed ID: 15560945
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Delivery systems for molecular vaccination.
    Sheikh NA; al-Shamisi M; Morrow WJ
    Curr Opin Mol Ther; 2000 Feb; 2(1):37-54. PubMed ID: 11249651
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Biomaterials as vaccine adjuvants.
    Jones KS
    Biotechnol Prog; 2008; 24(4):807-14. PubMed ID: 19194892
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antigen discovery and delivery of subunit vaccines by nonliving bacterial ghost vectors.
    Walcher P; Mayr UB; Azimpour-Tabrizi C; Eko FO; Jechlinger W; Mayrhofer P; Alefantis T; Mujer CV; DelVecchio VG; Lubitz W
    Expert Rev Vaccines; 2004 Dec; 3(6):681-91. PubMed ID: 15606353
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Targeting the innate immune response with improved vaccine adjuvants.
    Pashine A; Valiante NM; Ulmer JB
    Nat Med; 2005 Apr; 11(4 Suppl):S63-8. PubMed ID: 15812492
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Molecularly engineered poly(ortho ester) microspheres for enhanced delivery of DNA vaccines.
    Wang C; Ge Q; Ting D; Nguyen D; Shen HR; Chen J; Eisen HN; Heller J; Langer R; Putnam D
    Nat Mater; 2004 Mar; 3(3):190-6. PubMed ID: 14991022
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Vaccine adjuvant systems: enhancing the efficacy of sub-unit protein antigens.
    Perrie Y; Mohammed AR; Kirby DJ; McNeil SE; Bramwell VW
    Int J Pharm; 2008 Dec; 364(2):272-80. PubMed ID: 18555624
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Targeting dendritic cells for priming cellular immune responses.
    Gogolák P; Réthi B; Hajas G; Rajnavölgyi E
    J Mol Recognit; 2003; 16(5):299-317. PubMed ID: 14523943
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Trends in particulate antigen and DNA delivery systems for vaccines.
    Gander B
    Adv Drug Deliv Rev; 2005 Jan; 57(3):321-3. PubMed ID: 15560943
    [No Abstract]   [Full Text] [Related]  

  • 15. Nanoparticles and microparticles as vaccine-delivery systems.
    Singh M; Chakrapani A; O'Hagan D
    Expert Rev Vaccines; 2007 Oct; 6(5):797-808. PubMed ID: 17931159
    [TBL] [Abstract][Full Text] [Related]  

  • 16. "Pathogen-mimicking" nanoparticles for vaccine delivery to dendritic cells.
    Elamanchili P; Lutsiak CM; Hamdy S; Diwan M; Samuel J
    J Immunother; 2007; 30(4):378-95. PubMed ID: 17457213
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Particulate delivery systems for vaccines: what can we expect?
    Bramwell VW; Perrie Y
    J Pharm Pharmacol; 2006 Jun; 58(6):717-28. PubMed ID: 16734973
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Virus-like particles as HIV-1 vaccines.
    Doan LX; Li M; Chen C; Yao Q
    Rev Med Virol; 2005; 15(2):75-88. PubMed ID: 15484204
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Vaccine adjuvant systems containing monophosphoryl lipid A and QS21 induce strong and persistent humoral and T cell responses against hepatitis B surface antigen in healthy adult volunteers.
    Vandepapelière P; Horsmans Y; Moris P; Van Mechelen M; Janssens M; Koutsoukos M; Van Belle P; Clement F; Hanon E; Wettendorff M; Garçon N; Leroux-Roels G
    Vaccine; 2008 Mar; 26(10):1375-86. PubMed ID: 18272264
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Contemporary approaches to designing and evaluating vaccines against Chlamydia.
    Igietseme JU; Eko FO; Black CM
    Expert Rev Vaccines; 2003 Feb; 2(1):129-46. PubMed ID: 12901604
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.